COX2 Acetylating Composition for Alzheimer’s Neuroinflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for neurodegenerative diseases, such as Alzheimer's, fail to effectively address the dysregulation of glial cells and chronic inflammatory reactions caused by amyloid-β accumulation, leading to cognitive impairment and neuroinflammation.

Innovation Solution

A pharmaceutical composition comprising a COX2 acetylating agent that promotes the acetylation of COX2 by SphK1, enhancing the secretion of neuroinflammatory resolution factors like SPMs to restore microglial function and improve Aβ phagocytosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for neurodegenerative diseases, then general symptom management is provided, but they fail to address glial cell dysregulation and chronic neuroinflammation effectively

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidneuroinflammation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The invention converts the harmful chronic inflammatory state into a beneficial resolving state by promoting the production of SPMs (specialized proresolving mediators). Instead of merely suppressing inflammation, the composition actively promotes the transition from pro-inflammatory M1 microglia phenotype to anti-inflammatory M2 phenotype, thereby resolving neuroinflammation and its harmful effects on cognitive function.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention changes the biochemical parameters of the inflammatory response by modulating the expression and activity of COX-2 enzyme through acetylation. This post-translational modification alters the enzyme's function to produce pro-resolving mediators instead of pro-inflammatory prostaglandins, thereby transforming the inflammatory pathway from harmful to beneficial.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If microglia function is lost due to Aβ accumulation, then neuroinflammation progresses, but restoring microglia function requires addressing the underlying inflammatory dysregulation

Engineering Contradiction:

Improvemicroglia functionVSAvoidinflammatory dysregulation

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention introduces SPMs (specialized proresolving mediators) as intermediary substances that mediate the transition from pro-inflammatory to anti-inflammatory states. These mediators act as chemical messengers that communicate with microglia to restore their function, bridging the gap between Aβ accumulation and microglial dysfunction without directly addressing the amyloid burden.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-generated harmful factors

If COX-2 is inhibited conventionally, then prostaglandin production is reduced, but this does not promote SPM secretion or resolve neuroinflammation effectively

Engineering Contradiction:

Improvepro-inflammatory prostaglandinsVSAvoidSPM secretion

Core Design Contradiction:

Object-generated harmful factorsVSQuantity of substance

Solution Approach 1:

Instead of inhibiting COX-2 to reduce prostaglandin production, the invention inverts the approach by promoting COX-2 acetylation to enhance SPM production. This reverses the conventional wisdom that COX-2 inhibition is the only way to reduce inflammation, demonstrating that modulating COX-2 through acetylation can produce beneficial anti-inflammatory effects via SPMs.

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The COX2 acetylating agent increases COX2 acetylation, promoting the secretion of neuroinflammatory resolution factors, thereby reducing neuroinflammation and ameliorating Alzheimer-like lesions, improving cognitive function and motor capacity in animal models.

Implementation Method 1

SphK1 promotes the secretion of neuroinflammatory resolution factor by increasing the acetylation of COX2 (cyclooxygenase 2)

Methodology Applied

Scientific EffectAcetylation:

Data Source

PatentUS12399184B2Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising COX2 acetylating agent as active ingredient

Publication Date: 2025.08.26 KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND

AI summary

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.